Catheter ablation of atrial fibrillation using FireMagic TrueForce ablation catheter: The TRUEFORCE trial
Pacing and Clinical Electrophysiology · 2023
DOI: 10.1111/pace.14751 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pacing and Clinical Electrophysiology, 2023. Verfasst von Rongfeng Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pulmonary Veins, Catheter Ablation. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The use of contact force (CF) sensing catheters has provided a revolutionary improvement in catheter ablation (CA) of atrial fibrillation (AF) in the past decade. However, the success rate of CA for AF remains limited, and some complications still occur.
Methods
The TRUEFORCE trial (Catheter Ablation of Atrial Fibrillation using FireMagic TrueForce Ablation Catheter) is a multicenter, prospective, single‐arm objective performance criteria study of AF patients who underwent their first CA procedure using FireMagic TrueForce ablation catheter.
Results
A total of 120 patients (118 with paroxysmal AF) were included in this study, and 112 patients included in the per‐protocol analysis. Pulmonary vein isolation (PVI) was achieved in 100% of the patients, with procedure and fluoroscopy time of 146.63 ± 40.51 min and 12.89 ± 5.59 min, respectively. Freedom from recurrent atrial arrhythmia after ablation was present 81.25% (95% confidence interval [CI]: 72.78%–88.00%) of patients. No severe adverse events (death, stroke/transient ischemic attack [TIA], esophageal fistula, myocardial infarction, thromboembolism, or pulmonary vein stenosis) were detected during the follow‐up. Four (4/115, 3.33%) adverse events were documented, including one abdominal discomfort, one femoral artery hematoma, one coughing up blood, and one postoperative palpitation and insomnia.
Conclusions
This study demonstrated the clinical feasibility of FireMagic force‐sensing ablation catheter in CA of AF, with a satisfactory short‐ and long‐term efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, China.
- Department of Cardiology, Ningbo First Hospital, Ningbo, China.
- Department of Cardiology, Shanghai General Hospital, Shanghai, China.
- Department of Cardiology, Dongfang Hospital Affiliated to Tongji University, Shanghai, China.
- Department of Cardiology, Xuzhou Central Hospital, Xuzhou, China.
ORCID-Profile: Rongfeng Zhang, Huimin Chu, Shaowen Liu, Bing Han, Yunlong Xia
Zitieren
APA
Zhang, R., Chu, H., Liu, S., Yang, B., Han, B., Xiao, X., Ma, C., Sun, Y., Yin, X., Xia, Y., Gao, L., & TRUEFORCE investigators. (2023). Catheter ablation of atrial fibrillation using FireMagic TrueForce ablation catheter: The TRUEFORCE trial. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.14751
Vancouver
Zhang R, Chu H, Liu S, Yang B, Han B, Xiao X, et al. Catheter ablation of atrial fibrillation using FireMagic TrueForce ablation catheter: The TRUEFORCE trial. Pacing and Clinical Electrophysiology. 2023. doi:10.1111/pace.14751
BibTeX
@article{Zhang2023,
author = {Zhang, Rongfeng and Chu, Huimin and Liu, Shaowen and Yang, Bing and Han, Bing and Xiao, Xianjie and Ma, Chengming and Sun, Yuanjun and Yin, Xiaomeng and Xia, Yunlong and Gao, Lianjun and TRUEFORCE investigators., TRUEFORCE investigators.},
title = {Catheter ablation of atrial fibrillation using FireMagic TrueForce ablation catheter: The TRUEFORCE trial},
journal = {Pacing and Clinical Electrophysiology},
year = {2023},
doi = {10.1111/pace.14751}
}
EUVIMED